TREMELIMUMAB for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 51 adverse event reports in the FDA FAERS database where TREMELIMUMAB was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for TREMELIMUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pyrexia | 178 | 7.5% | 21 | 143 |
| Diarrhoea | 136 | 5.7% | 31 | 95 |
| Death | 116 | 4.9% | 116 | 17 |
| Colitis | 115 | 4.8% | 26 | 76 |
| Pneumonitis | 87 | 3.6% | 44 | 59 |
| Pneumonia | 85 | 3.6% | 36 | 76 |
| Sepsis | 82 | 3.4% | 35 | 71 |
| Vomiting | 78 | 3.3% | 11 | 70 |
| Febrile neutropenia | 72 | 3.0% | 30 | 60 |
| Malignant neoplasm progression | 68 | 2.9% | 22 | 9 |
| Abdominal pain | 64 | 2.7% | 22 | 60 |
| Dehydration | 61 | 2.6% | 21 | 58 |
| Biliary tract infection | 58 | 2.4% | 0 | 58 |
| Drug-induced liver injury | 57 | 2.4% | 11 | 36 |
| Dyspnoea | 57 | 2.4% | 23 | 32 |
Other Indications for TREMELIMUMAB
Pancreatic carcinoma (530)
Hepatocellular carcinoma (487)
Non-small cell lung cancer (448)
Pancreatic carcinoma metastatic (142)
Small cell lung cancer (80)
Squamous cell carcinoma of head and neck (68)
Bladder cancer (44)
Non-small cell lung cancer metastatic (44)
Neoplasm malignant (42)
Product used for unknown indication (25)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)